CD8A and neoplasm: In the Lewis lung carcinoma model, oxaliplatin combination with anti-PD-L1 induced ICD through activation of CD80+ CD86+ dendritic cells and enhanced cytotoxic T cells (CD8+), resulting in tumour regression [113].